Article
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2023
Gadgeel Shirish M, Miao Jieling, Riess Jonathan W, Moon James, Mack Philip C, Gerstner Gregory J, Burns Timothy F, Taj Asma, Akerley Wallace L, Dragnev Konstantin H, Laudi Noel, Redman Mary W, Gray Jhanelle E, Gandara David R, Kelly Karen
Abstract excerpt
PURPOSE: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and comutations. Our hypothesis was that docetaxel and trametinib would improve activity in KRAS+ NSCLC and specifically in KRAS G12C NSCLC. PATIENTS AND METHODS: S1507 is a single-arm phase II study assessing the response rate (RR) with docetaxel plus trametinib in recurrent KRAS+ NSCLC and secondarily in the G12C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.